[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ventricular-tachycardia-sustained\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ventricular-tachycardia-sustained":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,84],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100641935","cryoablation-for-monomorphic-ventricular-tachycardia-vts-100641935",false,"NCT07650032","Cryoablation for Monomorphic Ventricular Tachycardia (VTS)","Cryoablation for Monomorphic Ventricular Tachycardia IDE Study","FULCRUM-VT","Inclusion Criteria:\n\n* IC 1 Male or female ≥ 18 years\n* IC 2 Patients with a clinical indication for catheter ablation due to ischemic and\u002For non-ischemic heart disease and recurrent symptomatic sustained scar-mediated monomorphic Ventricular Tachycardia.\n* IC 3 Any of the following:\n\n  * Ischemic cardiomyopapthy (ICM) patients with prior history of myocardial infarction with Q waves, focal wall motion abnormality on imaging, fixed perfusion defect correlating with coronary stenosis or prior coronary intervention, 20% ≤ LVEF \\\u003C 50%.\n  * non-ischemic cardiomyopathy (NICM) patients with scar in a territory without coronary stenosis as evidenced by CMR imaging within the prior 90 days or intra-procedurally using EAM and PES prior to investigational device use, 20% ≤ LVEF \\\u003C 50%\n  * Arrhythmogenic right ventricular cardiomyopathy (ARVC)\n* IC 4 Has received a market-released ICD prior to enrollment\n* IC 5 Patient has had at least 1 documented spontaneous episode of SMVT within the previous 6 months\n* IC 6 Refractory to, or intolerant of, at least one Class III AAD. (Refractory or intolerant defined as AAD failure due to recurrent VT, not tolerated\u002F desired due to side effects)\n* IC 7 Willingness, ability, and commitment to participate in baseline and follow-up evaluations for the full length of the study\n* IC 8 Willingness and ability to give an informed consent\n\nExclusion Criteria:\n\n* EC 1 Intracardiac thrombus by TTE or TEE within 48 hours prior to the procedure\n* EC 2 Presence of isolated epicardial scar(s) requiring epicardial ablation identified by either preoperative CMR imaging within 90 days of procedure or intra-procedurally using EAM and PES prior to investigational device use\n* EC 3 VTs due to any of the following causes:\n\n  1. Idiopathic VT\n  2. Automaticity or triggered activity\n  3. Bundle Branch Reentry (BBR)\n  4. Any focal tachycardia (e.g., papillary, RVOT)\n  5. Ventricular tachycardia secondary to electrolyte imbalance, active thyroid disease, or any other reversible or non-cardiac cause\n* EC 4 NICM patients only, if any of the following apply:\n\n  1. Congenital condition that limits access to the left or right ventricles\n  2. Severe aortic or mitral stenosis, severe mitral regurgitation, or severe aortic insufficiency\n  3. Active inflammatory processes (e.g., myocarditis) within the past 120 days\n  4. Sarcoidosis\n  5. Hypertrophic cardiomyopathy\n  6. Drug- or alcohol-induced cardiomyopathy\n* EC 5 Any VT ablation within 4 weeks prior to enrollment\n* EC 6 More than one prior (\\>4 weeks) VT ablation or prior surgical treatment for VT within the past 2 years\n* EC 7 Cardiogenic shock, unless it is due to incessant monomorphic VT\n* EC 8 Any other cardiovascular conditions as described below:\n\n  1. Class IV heart failure\n  2. Aortic aneurysm\n  3. Previous cardiac surgery or percutaneous coronary intervention within 60 days prior to index procedure\n  4. Interatrial baffle, closure device, patch, or PFO occlusion device\n  5. Coronary artery bypass graft (CABG) procedure within six (6) months prior to the ablation procedure\n  6. Acute MI or unstable angina in the previous 60 days\n  7. Mechanical mitral or aortic valve\n  8. Cardiac myxoma\n  9. Significant congenital heart disease\n* EC 9 Acute illness or active systemic infection\n* EC 10 Any previous history of cryoglobulinemia\n* EC 11 History of blood clotting or bleeding disease\n* EC 12 Peripheral vascular disease that precludes LV access\n* EC 13 Contraindication to heparin\n* EC 14 Allergy to radiographic contrast dye that cannot be medically managed prior to the ablation procedure\n* EC 15 Any prior history of documented cerebral vascular accident (CVA), TIA or systemic embolism (excluding a post-operative Deep Vein Thrombosis, DVT), within 6 months prior to the ablation procedure.\n* EC 16 Pregnant, or anticipated pregnancy during study follow-up\n* EC 17 Current enrollment in any other study protocol where testing or results from that study may interfere with the procedure or outcome measurements for this study\n* EC 18 Any other condition (e.g., ARVC with extensive free wall scarring) that, in the judgment of the investigator, makes the patient a poor candidate for this procedure, the study or compliance with the protocol (includes vulnerable patient population, mental illness, addictive disease, candidate for heart transplantation, patient with ventricular assist device, or terminal illness with a life expectancy less than 12 months)","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","The objective of this clinical study is to evaluate the safety and effectiveness of the Adagio Medical vCLAS Ventricular Ablation System (including VTS Catheter and Console) in the ablation treatment of Sustained Monomorphic Ventricular Tachycardia (SMVT)",[27,28],"Ventricular Tachycardia, Sustained","Ventricular Tachycardia, Monomorphic",[30,31,32,33,34],"cryoablation","monomorphic VT","sustained monomorphic VT","Ultra Low Temperature Ablation","ULTA","NOT_YET_RECRUITING","2026-06-15",{"date":38,"type":39},"2026-06-17","ACTUAL",{"date":41,"type":21},"2026-08-01",{"date":43,"type":21},"2027-09-30",{"name":45,"class":46},"Adagio Medical","INDUSTRY",10,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":66,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":83},"100594316","stereotactic-radiosurgery-as-second-line-therapy-for-ventricular-tachycardia-100594316","NCT07017855","Stereotactic Radiosurgery as Second-line Therapy for Ventricular Tachycardia","STAR-4VT","Inclusion Criteria:\n\n1. Age ≥ 18 years at the time of enrollment.\n2. Presence of structural heart disease (SHD) of either ischemic or non-ischemic etiology.\n3. Implanted ICD or CRT-D device for primary or secondary prevention of sudden cardiac death (SCD).\n4. History of at least one endocardial CA procedure targeting a substrate of monomorphic sVT.\n5. Recurrence of at least one clinically significant and symptomatic episode of monomorphic sVT.\n6. Optimal pharmacological treatment of underlying SHD, including maximally tolerated doses of guideline-recommended heart failure therapies and appropriate antiarrhythmic management.\n7. Provision of written informed consent prior to study participation.\n\nExclusion Criteria:\n\n1. Reversible cause of sVT recurrence, particularly acute coronary syndrome (ACS), acute myocarditis, or lead-related infective endocarditis (LDIE).\n2. Myocardial infarction (MI) or cardiac surgery within the last 40 days.\n3. Idiopathic sVT unrelated to SHD or sVT associated with genetically determined channelopathies.\n4. Ongoing or persistently recurrent hemodynamically unstable sVT until clinical stabilization is achieved.\n5. Acute decompensation of heart failure, classified as New York Heart Association (NYHA) Class IV, until clinical stabilization is achieved.\n6. Worsening angina, classified as Canadian Cardiovascular Society (CCS) Class III or IV until coronary diagnostic evaluation and clinical stabilization are completed.\n7. A mobile thrombus within the left ventricle (LV).\n8. Presence of a left ventricular assist device (LVAD).\n9. Presence of comorbidities or known risk factors for CA complications that, in the judgment of the electrophysiologist, constitute a contraindication to the procedure for safety reasons.\n10. Active, uncontrolled malignancy and\u002For chemotherapy or immunotherapy administered or planned within 1 month of the scheduled ablation procedure.\n11. Features of an active systemic, pulmonary, or pericardial inflammatory process requiring systemic treatment (disease-modifying therapies, corticosteroids, immunosuppressants) within the past 6 months.\n12. Presence of comorbidities or known risk factors for radiotherapy complications that, in the judgment of the radiation oncologist, constitute a contraindication to STAR for safety reasons.\n13. Pregnancy or breastfeeding.\n14. Systemic disease that limits the probability of survival to less than 1 year\n15. Other comorbidities, addictions, or social indications that, in the investigator's opinion, would preclude practical cooperation or otherwise disqualify the patient from participation in the clinical study.\n16. Refusal to participate or lack of written informed consent for study participation.",{"count":56,"type":21},150,[24],"The aim of the study is to compare the efficacy and safety of treating recurrent sustained Ventricular Tachycardia (sVT) after prior Catheter Ablation (CA) in patients with Implanted Cardioverter-Defibrillator (ICD) between re-do of conventional endocardial CA and Stereotactic Arrhythmia Radioablation (STAR).",[28,27,60,61,62,63,64,65],"Ventricular Tachycardia (VT)","Ventricular Tachycardia (V-Tach)","Stereotactic Body Radiation Therapy (SBRT)","Stereotactic Techniques","Stereotactic Radiation","Cardioverter-Defibrillators, Implantable",[67,68,69,70,71,72],"Ventricular Tachycardia","VT","Stereotactic Arrhythmia Radioablation","STAR","Implanted Cardioverter-Defibrillator","ICD","2025-06-04",{"date":75,"type":39},"2025-06-12",{"date":77,"type":21},"2025-07-01",{"date":79,"type":21},"2028-11-01",{"name":81,"class":82},"Medical University of Silesia","OTHER",1,{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":22,"phases":94,"briefSummary":95,"conditions":96,"keywords":101,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":83},"100406723","a-danish-icd-study-in-patients-with-coronary-artery-disease-resuscitated-from-ventricular-fibrillation-100406723","NCT04576130","A Danish ICD-study in Patients with Coronary Artery Disease Resuscitated from Ventricular Fibrillation","A Danish Study to Assess the Efficacy of Implantable Cardioverter Defibrillator in Patients with Coronary Artery Disease Resuscitated from Ventricular Fibrillation Who Receive Complete Revascularization","DanICD","Inclusion Criteria:\n\n* Patients with CAD and cardiac arrest due to VF\u002FVT, where angiogram is performed with complete revascularization (PCI, CABG or hybrid coronary revascularization) before ICD implantation. Unfavorable artery for PCI (i.e., excessive vessel tortuosity or chronic total occlusion) or high-risk invasive treatment is not mandatory in order to achive complete revascularization.\n* Age ≥18 years\n* LVEF \\>35% at the time of discharge. The most recent LVEF assessment on which the current medical treatment will be based at the time of entry into the study will be used as baseline LVEF.\n\nExclusion Criteria:\n\n* Non-ischemic cause of cardiac arrest (i.e. ion channel diseases, non-ischemic cardiomyopathy)\n* Previous CABG within the last 3 months before index hospitalization\n* Life expectancy less than 1 year or severe neurologic outcome\n* Unable or unwilling to give informed consent\n* Pregnancy",{"count":93,"type":21},1200,[24],"DanICD is a randomized, controlled study to with the aim to assess whether there is a benefit of ICD-implantation in patients with coronary artery disease (including acute myocardial infarction), who survive cardiac arrest due to ventricular fibrillation\u002Fsustained ventricular tachycardia and undergo revascularization and with an LVEF above 35%.",[97,98,99,27,100],"Coronary Artery Disease","Acute Myocardial Infarction","Ventricular Fibrillation","Out-Of-Hospital Cardiac Arrest",[102,103,104],"Revascularization","Percutaneous coronary intervention","Implantable cardioverter defibrillator","RECRUITING","2025-01-23",{"date":108,"type":39},"2025-01-27",{"date":110,"type":39},"2020-10-12",{"date":112,"type":21},"2032-10",{"name":114,"class":82},"Rigshospitalet, Denmark"]